What you're saying makes complete sense. I just struggle at times with decisions like these because because there are millions of people sick today where the

What you're saying makes complete sense. I just struggle at times with decisions like these because because there are millions of people sick today where the disease has broken through Avastin's ability to constrain tumor size and this might be what's needed to put it over the edge. On the other hand, anti-angiogenics are frequently not even made available in a post surgery context, particularly if perforations are a concern, so having some kind of agent that can throttle tumor growth without impacting compromised tissue would be a benefit. I guess there are no good answers until we can do whole body simulations to test drugs and all of their corner cases en masse.